|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 6,440,458
Patent Overview
U.S. Patent 6,440,458, granted on August 27, 2002, to Eli Lilly and Company, covers a class of compounds and their use as kinase inhibitors, primarily targeting Cyclin-Dependent Kinases (CDKs) for cancer treatment. The patent claims compositions, methods of use, and methods of synthesis related to these molecules.
Scope of the Patent
The patent claims a specific chemical class of compounds with a heterocyclic basis designed to inhibit CDK activity. It covers:
- Chemical compounds: Structurally characterized by a core heterocyclic system with specific substituents (see detailed chemical formulae below).
- Uses: Methods of inhibiting CDK activity, especially in the context of cancer cell proliferation.
- Methods of synthesis: Step-by-step protocols for preparing the compounds.
- Pharmaceutical compositions: Formulations suitable for administration.
Key Features of the Claims:
- Mention of specific substituents at defined positions on the heterocyclic core.
- Definitions of biological activity thresholds, primarily the inhibition of CDK2, CDK4, and CDK6.
- Covering both the compounds themselves and their pharmaceutically acceptable derivatives.
- Inclusion of methods for treating cancers such as breast, prostate, and other solid tumors with the compounds.
Claims Breakdown
The patent contains 36 claims. The most central are independent claims 1 and 20, covering the compounds and their methods of use, respectively.
Claim 1 (Scope of compounds):
- Defines a chemical compound with a heterocyclic core, substituted at specific positions with variable groups denoted as R1, R2, R3, R4, and so forth.
- The groups R1–R4 are selected from a set of possible chemical entities, with restrictions on steric and electronic properties.
- The compounds are characterized by their CDK inhibitory activity, with an in vitro IC50 value below a specified threshold (e.g., less than 1 μM).
Claim 20 (Use of compounds):
- Claims a method of inhibiting CDK activity in a mammal by administering an effective amount of the compound described in claim 1.
- The method extends to treating cancer, specifically mentioning breast and prostate cancer.
Dependent Claims:
- Narrow down the scope with specifics on substituent groups.
- Include formulations and dosage regimens.
Patent Landscape and Related Patents
Family and Related Patents
- The patent belongs to a larger patent family, which includes filings in Europe, Japan, and other jurisdictions.
- Related patents include WO 02/055978 (published application from Lilly), which elaborates on kinase inhibitors with similar core structures but different substituents.
Patent Citations and Interactions
- Cited patents encompass various kinase inhibitors and cancer therapeutics, including other CDK inhibitors and tyrosine kinase antagonists.
- This patent is part of a competitive landscape involving compounds from companies such as Pfizer, Merck, and Novartis, which develop kinase inhibitors for cancer therapy.
Patent Expiry and Freedom to Operate
- The patent expires in 2022, barring any Patent Term Extensions or supplementary protection certificates (SPCs).
- Its expiration marks an increase in generic and biosimilar development for CDK inhibitors.
Market and Development Status
- CDK inhibitors like palbociclib (Ibrance) have progressed to market, but Lilly's compounds covered in this patent remain largely experimental.
- Patent claims have influenced in vitro research but have limited direct commercial use due to their narrow target scope and competition.
Implications for R&D and Investment
- The scope offers potential for new compounds by modifying substituents, especially if lead compounds with improved selectivity and pharmacokinetics are identified.
- The patent's expiration potentially allows generic development and biosimilar competition.
- The broad claims on chemical structures provide a foundation but also face challenge from narrower, more specific patents.
Summary
U.S. Patent 6,440,458:
- Defines a class of heterocyclic kinase inhibitors targeted towards CDKs for cancer.
- Provides detailed chemical scope, targeting molecules with specified structural features.
- Outlines methods of use, including treatment of specific cancers.
- Is part of an active patent landscape involving kinase inhibitor research and development.
- Expires in 2022, opening opportunities for generics and further innovation.
Key Takeaways
- The patent covers broad chemical classes with activity against key cell cycle kinases.
- Its claims focus on specific structural features linked to biological activity.
- The patent’s expiration could catalyze new development efforts.
- Related patents and ongoing research expand the landscape for kinase inhibitors.
- Companies looking to innovate should consider modifications outside the patent’s scope to avoid infringement.
FAQs
1. How broad are the claims of U.S. Patent 6,440,458?
They cover a class of heterocyclic compounds with specific substituents, claiming the chemical structure, use for CDK inhibition, and pharmaceutical compositions.
2. What is the main therapeutic application of these compounds?
They are intended primarily for treating cancers, especially breast and prostate cancer, by inhibiting CDK activity.
3. When does the patent expire, and what does that mean for developers?
Expiration is scheduled for 2022, after which generic developers can produce similar compounds without infringing on the patent.
4. How does this patent interact with other kinase inhibitor patents?
It cites and overlaps with patents covering related compounds, forming a complex landscape that requires careful navigation for new R&D.
5. Are there existing drugs derived from this patent’s compounds on the market?
No, these specific compounds have not been marketed, although other CDK inhibitors like palbociclib have succeeded.
References
[1] U.S. Patent 6,440,458.
[2] Lilly patent family documents and related filings.
[3] Public databases such as Lens.org and Espacenet for patent family and citation analysis.
More… ↓
⤷ Start Trial
|
